Russian Federation
Federal State Budgetary Educational Institution of Additional Professional Education "Russian Medical Academy of Continuous Professional Education" (Department of Therapy and Adolescent Medicine, Applicant)
Russian Federation
Federal State Budgetary Educational Institution of Additional Professional Education "Russian Medical Academy of Continuous Professional Education" (Department of Therapy and Adolescent Medicine, Associate Professor)
Russian Federation
Russian Federation
Acute decompensation of heart failure is one of the main causes of repeated hospitalizations and worse survival rate. Studies aimed at exploring new opportunities to improve clinical status and prognosis remain highly relevant. Early administration of the type 2 sodium-glucose cotransporter inhibitors (iNGLT-2), in particular dapagliflozin, looks promising.
dapagliflozin, type 2 sodium-glucose cotransporter inhibitors, acute decompensation of chronic heart failure
1. Kitakata H. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: A report from a Japanese multicenter registry / Kitakata H., Kohno T., Kohsaka \ S., Shiraishi Y., Parizo J.T., Niimi N., Goda A., Nishihata Y., Heidenreich P.A., Yoshikawa T. // J Am Heart Assoc. – 2020; 9(10):e014949. doi:https://doi.org/10.1161/JAHA.119.014949
2. Njoroge J.N. Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure / Njoroge J.N., Teerlink J.R. // Circulation Research. – 2021; 128(10):1468–1486. doi: 10.1161/ CIRCRESAHA.121.318186
3. Cardoso R. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis / Cardoso R., Graffunder F., Ternes C. // EClinicalMedicine. – 2021;36:100933. doi:https://doi.org/10.1016/j.eclinm.2021.100933
4. Abdelrahman N. Emara, Moheb Wadie, Noha O. Mansour, Mohamed E.E. Shams. The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPARESPONSE- AHF) // Eur J Pharmacol. – 2023: 961:176179. doi:https://doi.org/10.1016/j.ejphar.2023.176179
5. Bhatt D.L. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure / Bhatt D.L., Szarek M., Steg P.G., Cannon C.P., Leiter L.A., McGuire D.K., Lewis J.B., Riddle M.C., Voors A.A., Metra M., Lund L.H., Komajda M., Testani J.M., Wilcox C.S., Ponikowski P., Lopes R.D , Verma S., Lapuerta P., Pitt B. // New England Journal of Medicine. – 2021; 384 (2):117–128. doi:https://doi.org/10.1056/NEJMoa2030183
6. Voors A.A. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial / Voors A.A., Angermann C.E., Teerlink J.R., Collins S.P., Kosiborod M., Biegus J., Ferreira J.P., Nassif M.E., Psotka M.A., Tromp J., Borleffs C.J.W., Ma C., Comin-Colet J., Fu M., Janssens S.P., Kiss R.G., Mentz R.J., Sakata Y., Schirmer H., Schou M., Schulze P.C., Spinarova L., Volterrani M., Wranicz J.K., Zeymer U., Zieroth S., Brueckmann M., Blatchford J.P., Salsali A., Ponikowski P. // Nature Medicine. – 2022; 28( 3):568–574. doi:https://doi.org/10.1038/s41591-021-01659-1
7. Noor Ul Amin, Faiza Sabir, Talal Amin, Zouina Sarfraz, Azza Sarfraz, Karla Robles-Velasco, Ivan Cherrez-Ojeda. SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials // Healthcare (Basel). – 2022; 10(12): 2356. doi:https://doi.org/10.3390/healthcare10122356
8. Carvalho P.E. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials / Carvalho P.E., Veiga T.M., Simões e Silva A.C., Gewehr D.M., Dagostin C.S., Fernandes A., Nasi G., Cardoso R. // Clinical Research in Cardiology. – 2023; 112 (8): 1044–1055. doi:https://doi.org/10.1007/s00392-022-02148-2
9. Charaya K. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study / Charaya K., Shchekochikhin D., Andreev D., Dyachuk I., Tarasenko S., Poltavskaya M., Mesitskaya D., Bogdanova A., Ananicheva N., Kuzub A. // Open Hear. – 2022: 9 (1): e001936. doi:https://doi.org/10.1136/openhrt-2021-001936
